1Y Annualised Return
▲50.35%
3Y Annualised Return
▲25.83%
5Y Annualised Return
▲25.14%
10Y Annualised Return
▲0.63%
Concord Drugs Stock Performance
|
|
|
Concord Drugs Company background
Founded in: 1995
Managing director: S Nagi Reddy
Concord Drugs Limited, established in 1995, is amongst the respected pharmaceutical companies in India for manufacturing of Finished Pharmaceutical Formulations like Injectables (Small Volume parenterals, Dry Syrup powder) ,Tissue BioAdhesive, tablets, capsules and ophthalmic preparations and Readytofill Pellets. The principal activity of the Company is to manufacture licensed drugs based on the formulations approved. The Company has two manufacturing facilities license issued by The Government of Andhra Pradesh, Drugs Control Administration, and Hyderabad. State of the art technology having dedicated manufacturing facilities for Liquid Injections, Dry powder Injections and Readytofill Pellets ensures the highest level of process integrity and product quality.The Company started with Finished Pharmaceutical Formulations and then diversified into Readytofill Pellets, to provide customers with endtoend solution to their various pharmaceutical product needs to commercial contract drug manufacturing. It is engaged in developing New products Viz MUPS (Multiple Unit Pellet System), Sustained Release, Modified Release pellets with Innovative Drug Delivery Technologies by utilizing best and latest processing machinery. It operates a state of the art, cGMP contract manufacturing FormulationFillFinish facility, providing comprehensive pharmaceutical development and manufacturing services for drug products.
Concord Drugs Financial Highlights
Concord Drugs reported a Q2 FY2025–2026 revenue of ₹13.61 crore, up 0.7% YoY, with net profit decreased -27.7% to ₹0.12 crore. For the full year FY2025–2026, revenue reached ₹45.26 crore and profit touched at ₹0.34 crore. As of Jun '25, Concord Drugs’s market capitalisation stood at ₹49.98 crores. Shareholding as of Jun '25 shows promoters holding 54.4%, with FIIs at 45.6%, DIIs at %, and public at %.
As of 20 Aug, 2025, Concord Drugs share price is ₹50. The stock opened at ₹50 and had closed at ₹50 the previous day. During today’s trading session, Concord Drugs share price moved between ₹49.98 and ₹49.98, with an average price for the day of ₹49.98. Over the last 52 weeks, the stock has recorded a low of ₹26.10 and a high of ₹67.00. In terms of performance, Concord Drugs share price has increased by 45.7% over the past six months and has increased by 50.35% over the last year.
Concord Drugs SIP Return Calculator
Over the past
1 year
3 years
5 years
Total Investment of ₹65,00,000
Would have become ₹84,55,324 (+30.08%)
Daily SIP of ₹25,000 would have become ₹84,55,324 in 1 year with a gain of ₹19,55,324 (+30.08%)
Concord Drugs Fundamental
Market Cap (in crs)
49.98
Face Value
10
Turnover (in lacs)
0.09
Key Metrics
Qtr Change %
25.40% Fall from 52W High
55.1
Dividend yield 1yr %
0
Concord Drugs Key Financials
Loading chart...
Loading chart...
Loading chart...
Loading chart...
Concord Drugs Quarterly Revenue
| Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|
13.61 Cr | 10.39 Cr | 10.8 Cr | 12.36 Cr | 11.69 Cr |
Concord Drugs Yearly Revenue
| Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|
45.26 Cr | 44.93 Cr | 52.09 Cr |
Concord Drugs Quarterly Net Profit/Loss
| Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|
0.12 Cr | 0.04 Cr | 0.23 Cr | 0.04 Cr | 0.03 Cr |
Concord Drugs Yearly Net Profit/Loss
| Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|
0.34 Cr | 0.47 Cr | 0.99 Cr |
Concord Drugs Technical Analysis
Moving Averages Analysis
Moving Averages Analysis
49.98
Current Price
5Day EMA
51.70
10Day EMA
53.00
12Day EMA
53.40
20Day EMA
53.90
26Day EMA
53.50
50Day EMA
49.90
100Day EMA
44.40
200Day EMA
40.50
5Day SMA
52.00
10Day SMA
53.50
20Day SMA
55.10
30Day SMA
57.30
50Day SMA
49.00
100Day SMA
40.20
150Day SMA
38.20
200Day SMA
37.90
Delivery & Volume
| Period | Combined Delivery Volume | NSE+BSE Traded Volume |
|---|---|---|
Day Rs | 5191 Rs | 5191 Rs |
Week Rs | 3832 Rs | 3832 Rs |
Month Rs | 6475 Rs | 6475 Rs |
Resistance & Support
50.32
Pivot
Resistance
First Resistance
50.66
Second Resistance
51.34
Third Resistance
51.68
Support
First Support
49.64
Second support
49.30
Third Support
48.62
Relative Strength Index
38.28
Money Flow Index
38.73
MACD
-0.08
MACD Signal
1.18
Average True Range
1.68
Average Directional Index
23
Rate of Change (21)
-17.81
Rate of Change (125)
48.40
Concord Drugs Peer comparison
| Index Name | Market Price | Market Cap | 52W Low | 52W High | Prev. Close | 1W Return | 1M Return | 6M Return | 1Y Return | 3Y Return | Dividend Yield | PE Ratio | Industry PE | PB Ratio |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
39.50 | 48.77 | 37.2 | 61 | 39.11 | -0.95% | -9.20% | -10.43% | -18.82% | -12.32% | 0.00% | 100.28 | 103.50 | 0.72 | |
18.81 | 46.73 | 8.71 | 22.77 | 19.71 | -6.84% | -9.61% | 78.13% | 115.96% | 318.93% | 0.00% | 0.00 | 40.64 | 1.90 | |
50.00 | 46.99 | 43.75 | 69.5 | 48.64 | 4.71% | 0.00% | -5.87% | -19.11% | -27.22% | 0.00% | 29.30 | 40.64 | 1.12 | |
179.95 | 55.11 | 170 | 345 | 173.40 | -4.54% | -13.40% | -29.33% | -43.89% | 52.56% | 0.00% | 14.00 | 40.64 | 1.55 | |
20.99 | 50.47 | 6.4 | 26.31 | 20.08 | 4.85% | -13.30% | 74.48% | 193.98% | 0.00% | 0.00% | 51.20 | 40.64 | 1.31 | |
45.00 | 52.02 | 35.7 | 69.7 | 45.80 | 2.27% | 1.93% | -7.88% | -16.26% | 0.00% | 0.00% | 7.19 | 40.64 | 1.25 |
Concord Drugs Share Price FAQs
How to buy Concord Drugs shares?
You can easily buy Concord Drugs shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.
What is the 52-week high and low of Concord Drugs ?
The 52-week high and low of Concord Drugs share price is ₹67 and ₹26.1 as of 20/8/2025.
Please be aware that Concord Drugs stock prices are subject to continuous fluctuations due to various factors.
Open Demat Account